NCT01380717

Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)

The Role of Renal and Peripheral Vascular Resistance in Chronic Kidney Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

Patients with reduced kidney function have a higher risk of heart disease and death. Studies have shown that blood vessels in patients with hypertension change with a decrease of lumen size and growth of the vessel wall. By treating patients with antihypertensive certain medication vessel lumen and walls normalize. Treating hypertension in patients with chronic kidney disease slows the progression of kidney function loss. The aim is to compare different degrees of antihypertensive medication in patients with chronic kidney disease and hypertension will slow the progression of kidney loss.

Conditions

• Chronic Kidney Insufficiency
• Hypertension
• Vasodilation

Interventions

Type	Name	Description
DRUG	Beta-blocker, ACE-inhibitor	Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
DRUG	Calcium Channel Blockers, ACE-Inhibitor	Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day

Timeline

• Start date: 2011-02-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2011-06-27
• Last updated: 2014-02-27

Locations

1 site across 1 country: Denmark